Preclinical activity of ELVN-002: A potent, selective, and irreversible HER2 and pan-HER2 mutant small molecule inhibitor for the treatment of HER2 driven malignancies Monette Aujay, Amanda J. Broad, Stefan D. Gross, Li Ren,Joseph P. Lyssikatos, Samuel Kintz, Qi Wang,Helen CollinsCANCER RESEARCH（2023）引用 0|浏览0暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
